Significance of HOX11L2/TLX3 expression in children with T-cell acute lymphoblastic leukemia treated on Children's Cancer Group protocols Leukemia (2005) T-cell acute lymphoblastic leukemia (T-ALL) accounts for approximately 15% of cases of childhood ALL. In earlier pediatric ALL clinical trials, the T-cell phenotype was associated with an unfavorable prognosis. However, the use of modern risk-adjusted multiagent treatment regimes has been reported to override this difference. While a 5-year event-free survival rate of approximately 70-75% is currently achieved in childhood T-ALL, a significant proportion of patients continue to relapse. Importantly, relapsed T-ALL confers an extremely poor prognosis.
With improvements in the outcome of patients with T-ALL there is a pressing need to identify prognostic molecular markers to aid patient stratification. This is especially important since, in contrast to B-lineage ALL, cytogenetic abnormalities in T-ALL have failed to provide comparable prognostic information. 1 Studies have revealed that certain transcription factors associated with T-ALL might be useful for prognosis. The most notable examples are HOX11/TLX1 and HOX11L2/TLX3, two structurally related homeobox genes. HOX11 is aberrantly expressed in childhood T-ALL as a result of either of two chromosomal translocations, t(7;10)(q35;q24) and t(10;14)(q24;q11), which place the HOX11 coding sequence under the transcriptional control of T-cell receptor regulatory elements. HOX11L2 is involved in a cryptic translocation, t(5;14)(q35;q32), detectable only by FISH.
2 Both pediatric and adult T-ALL patients expressing HOX11 in their blast cells have been demonstrated to have an excellent prognosis. [3] [4] [5] On the other hand, the prognostic significance of HOX11L2 expression is equivocal. Two studies reported expression of this gene to be associated with a very poor prognosis 4, 6 whereas a larger study revealed no difference in prognosis. 7 Quantitative real-time RT-PCR (qRT-PCR) (TaqMan) technology was employed to determine the level of expression of HOX11L2 and HOX11 in 40 diagnostic pediatric T-ALL bone marrow specimens obtained from patients treated on Children's Cancer Group (CCG) risk-adjusted protocols between 1984 and 2002. T-ALL lymphoblasts are thought to originate from normal T-lymphocyte precursors arrested at various stages of thymocyte development. Putative normal cellular counterparts comprising normal CD34 þ bone marrow (stem) cells (n ¼ 3), normal thymocytes (n ¼ 6) and peripheral T cells (n ¼ 6) were included as controls. qRT-PCR analysis was performed and expression levels of test genes were determined as a ratio to a reference gene, ACTB, as previously described. 5 The reference cell lines used were PER-255 for HOX11 and PER-487 for HOX11L2. For the gene HOX11L2 primers and probe were obtained from Applied Biosystems (ABI Assays on Demand, www.appliedbio systems.com). All samples were tested in duplicate. KaplanMeier survival analysis was conducted on relapse-free survival (RFS) and overall survival (OS) data. The log-rank test was used for comparison of outcome for patient groups according to the expression of HOX11L2 and HOX11. w 2 test and Fisher's exact test were used to assess patient characteristics.
HOX11L2 and HOX11 expression were undetectable in all 15 controls, thus any level of detection in patient specimens was regarded as positive expression of either HOX11 or HOX11L2. Seven (18%) of the patient specimens expressed HOX11L2 compared with ten (25%) for HOX11. Only three of the 10 (7.5% of the whole cohort) HOX11-positive specimens exhibited high expression levels. The average expression level of the high HOX11 expressors was approximately 550 times higher (mean 0.89 (range 0.1-1.99)) than for low HOX11 expressors (mean 0.0016 (range 0.00009-0.0095)). The significance of low-level expression of HOX11 is not known and most investigators include only high HOX11 expressors in their analysis. 3, 4, 7, 8 In contrast, HOX11L2 was expressed at high levels in all specimens (mean 2.08 (range 0.3-8.74)) ( Figure 1 ). These results are consistent with previously published frequencies since HOX11L2 expression in pediatric T-ALL was reported to range from 10 to 24% (mean 20%). 2, 4, [6] [7] [8] [9] On the other hand, 6-20% (mean 11%) of pediatric T-ALL specimens expressed high levels of HOX11 4-9 compared with 4-29% (mean 13%) for low levels of HOX11 expression. [4] [5] [6] In agreement with other studies, HOX11L2 and high levels of HOX11 expression were found to be mutually exclusive. 4, [6] [7] [8] [9] One of our specimens expressed HOX11L2 (level of 0.3) in combination with a low level (0.0005) of HOX11 (marked by arrow in Figure 1 ). The expression of HOX11L2 in association with low levels of HOX11 has been previously demonstrated 8 and is of unknown significance.
Cytogenetic analysis was successful in 65% (26/40) of specimens and of these 58% (15/26) revealed a chromosomal abnormality. None of the patient samples expressing HOX11 were found to have a translocation involving t(7;10) or t(10;14), further supporting the observation that HOX11 deregulation can occur in the absence of these translocations.
3-7 Insufficient material was available for FISH analysis to detect t(5;14)(q35;q32) in specimens expressing HOX11L2.
To examine gene expression in leukemia cells and clinical outcome, we estimated the 5-year RFS rate and the OS rate, which was feasible for 39 patients. The median follow-up time for nonrelapse patients was 4.5 years (range 1.2-12.8 years). A total of 13 (33%) patients relapsed, with a median time of 2 years (range 7.7 months-4.2 years). One patient failed to achieve remission, with greater than 25% blasts in the bone Expression of HOX11L2/ACTB and HOX11/ACTB in 40 pediatric T-ALL specimens. Only specimens expressing HOX11L2 (n ¼ 7) and HOX11 (n ¼ 10) are depicted. A solid black line separates high and low expressors. The arrow denotes patient specimen that expresses both HOX11L2 and HOX11. Correspondence marrow (M3) by the end of induction and died a short time later from sepsis. This patient's blasts did not express HOX11L2 or HOX11. The 5-year RFS rate for all cases was 64% (s.e.78%) and the OS rate was 56% (s.e.79%). Patients whose T-ALL cells expressed HOX11L2 had an excellent prognosis (100% 5-year RFS) compared to those not expressing HOX11L2 (54% (s.e.79%)) (P ¼ 0.04) (Figure 2a) contrasting with other reports. There was no significant difference in the 5-year RFS rate according to HOX11 expression in blast cells, for HOX11 high level 33% (s.e.727%) vs HOX11 low level 57% (s.e.719%) vs HOX11-negative 69% (s.e.79%) (P ¼ 0.56) (Figure 2b) . Accordingly, the comparison between HOX11-positive (high and low levels) vs HOX11-negative revealed no significant difference in the 5-year RFS. The 5-year RFS was 50% (s.e.716%) for HOX11-positive vs 69% (s.e.79%) for HOX11-negative patients (P ¼ 0.29). The OS with respect to expression of both genes essentially mirrored the RFS (Figure 2c and d) . A statistically significant difference in 5-year RFS rate for girls compared to boys, 100 vs 53% (s.e.79%) (P ¼ 0.03) was noted, a feature often observed in T-ALL. Sex ratio among HOX11L2 expressors was not significantly different from that of nonexpressors (P ¼ 0.32), suggesting that gender does not explain the prognostic effect of HOX11L2 expression. There were no statistically significant associations between the expression of HOX11 or HOX11L2 and white cell count (WCC), age or status of day 7 bone marrow. Furthermore, we found no significant difference in 5-year RFS rate according to WCC, age or status of day 7 bone marrow. This is the first study demonstrating a favorable prognosis associated with the expression of HOX11L2 in T-ALL blasts. The observed differences in outcome could be due to the relatively small patient cohort investigated. This may also be the situation for the two studies demonstrating a poor prognosis associated with HOX11L2 expression, 4, 6 particularly since the significantly larger study conducted by Cavé et al 7 reported no difference in the outcome of pediatric patients whose leukemia cells expressed HOX11L2. Alternatively, the prognostic impact of HOX11L2 expression may be dependent upon the therapeutic regimen utilized. Indeed, distinct treatment strategies compared to those used in this study were employed in the studies reporting a poor prognosis associated with the aberrant expression of HOX11L2. 4, 6 The majority of patients in the present study were treated on CCG-modified BFM (BerlinFrankfurt-Mû nster) protocols. This notion is supported by our previous findings showing that the good prognosis associated with HOX11 expression was evident only for patients on a particular treatment protocol, implying that HOX11-positive cells may be more sensitive to specific therapies compared to HOX11-negative cells. 5 On the other hand, in the study conducted by Cavé et al, 7 patients were also treated with BFM-based therapy, and no difference was found in the outcome of patients whose blasts expressed HOX11L2. However, the authors commented that their data was consistent with the premise that HOX11L2 expression may be associated with a good prognosis, by virtue of a higher proportion of HOX11L2-expressing samples displaying CD1a þ (cortical/intermediate) immunophenotype, that has been associated with a superior prognosis. The most notable difference in therapy that may account for the improved outcome of the patient cohort expressing HOX11L2 investigated in this study compared to the two studies which revealed association with poor prognosis 4, 6 is the inclusion of a reintensification (reinduction) phase, a critical component of BFM therapy for ALL. A reintensification phase was not included in the treatment protocol (FRALLE 93 very high-risk arm) of a significant proportion of patients (33%) investigated by Ballerini et al 6 or for two of the three protocols (St Jude Total Therapy Studies XI and XII) utilized to treat patients studied by Ferrando et al. 4 In contrast, these treatment protocols applied alternative therapeutic strategies.
The favorable prognosis reported to be associated with HOX11 expression was not replicated in this study. This may have been due to the size of the study. Using microarray technology, Ferrando et al 3 found that HOX11-positive cells expressed several genes associated with cellular proliferation. Thus, the authors proposed that the better prognosis for patients with HOX11-positive could be linked to the high proliferation rate, making them more susceptible to the effects of chemotherapy, which preferentially targets actively dividing cells. Furthermore, these investigators demonstrated that specimens expressing HOX11L2 had remarkably similar genetic profiles to HOX11 expressing specimens, except for notable differences in several genes involved in signal transduction and chromatin related genes associated with HOX11-positive cells. Considering the similarities between HOX11 and HOX11L2, it is equally plausible that patients, whose leukemic blasts express either of these two genes, should have similar prognosis. Hence, the strikingly different patient outcome between patients with HOX11 and HOX11L2-positive cells was very surprising. 4 While, the relatively small number of patient specimens investigated in this study precludes any definite conclusions, the marked difference in outcome observed here for patients with HOX11L2-expressing cells compared to other studies supports the principle that specific biological subtypes of leukemia may be more sensitive to distinct therapeutic regimes. Analysis of a larger cohort of uniformly treated patients is warranted to verify these results.
